For USD 17.5 million
Dr Reddys Laboratories announced that it has completed the purchase of worldwide exclusive intellectual property rights for Fondaparinux sodium, its generic anti-coagulant drug from its Australian partner, Alchemia. Earlier, the company has signed a term sheet for this transaction for this transaction in September 2015.Alchemia has received USD 17.5 million from Dr Reddys as consideration for the sale. The agreement is effective July 2015.
Powered by Capital Market - Live News
